Loading...
OTCM
PMKIF
Market cap91mUSD
Jan 10, Last price  
2.14USD
Name

Merck Tbk PT

Chart & Performance

D1W1MN
P/E
90.08
P/S
16.70
EPS
397.86
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
9.46%
Revenues
961.43b
-14.51%
386,345,803,000487,601,198,000547,237,994,000637,134,080,000751,403,033,000795,688,800,000918,532,462,000929,876,824,0001,193,952,302,000863,207,535,000983,446,471,0001,034,806,890,0001,156,648,155,000611,958,076,000744,634,530,000655,847,125,0001,064,394,815,0001,124,599,738,000961,433,965,000
Net income
178.24b
-0.89%
57,700,045,00086,537,702,00089,484,528,00098,620,070,000146,700,178,000118,794,278,000231,158,647,000107,808,155,000175,444,757,000181,472,234,000142,545,462,000153,842,847,000144,677,294,0001,163,324,165,00078,256,797,00071,902,263,000131,660,834,000179,837,759,000178,240,003,000
CFO
203.87b
+8.17%
000000088,404,562,000133,099,062,000232,826,497,000160,700,345,00043,799,001,000129,919,801,000168,964,859,000-210,843,887,00071,983,458,000169,814,591,000188,483,757,000203,874,886,000
Earnings
May 29, 2025

Profile

PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in discovering, developing, manufacturing, and marketing pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders comprising hyperthyroidism and hypothyroidism. In addition, it leases and manages properties. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. PT Merck Tbk is a subsidiary of Merck Holding GmbH.
URL
https://www.merckgroup.com/id-id
IPO date
Jul 23, 1981
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
961,433,965
-14.51%
1,124,599,738
5.66%
Cost of revenue
762,491,298
790,136,498
Unusual Expense (Income)
NOPBT
198,942,667
334,463,240
NOPBT Margin
20.69%
29.74%
Operating Taxes
24,892,983
57,940,610
Tax Rate
12.51%
17.32%
NOPAT
174,049,684
276,522,630
Net income
178,240,003
-0.89%
179,837,759
36.59%
Dividends
(143,890,033)
(107,265,442)
Dividend yield
7.68%
5.04%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
6,936,890
6,452,768
Long-term debt
29,328,530
25,913,560
Deferred revenue
Other long-term liabilities
25,708,113
31,600,766
Net debt
(165,171,405)
(138,061,976)
Cash flow
Cash from operating activities
203,874,886
188,483,757
CAPEX
(19,184,162)
(20,184,727)
Cash from investing activities
(19,902,571)
(19,997,727)
Cash from financing activities
(152,963,794)
(116,240,168)
FCF
74,538,997
217,828,409
Balance
Cash
201,436,825
170,428,304
Long term investments
Excess cash
153,365,127
114,198,317
Stockholders' equity
778,317,276
739,680,132
Invested Capital
686,354,489
642,763,839
ROIC
26.19%
46.76%
ROCE
23.69%
44.18%
EV
Common stock shares outstanding
448,000
448,000
Price
4,180.00
-12.00%
4,750.00
28.73%
Market cap
1,872,640,000
-12.00%
2,128,000,000
28.73%
EV
1,707,468,595
1,989,938,024
EBITDA
231,261,612
343,109,238
EV/EBITDA
7.38
5.80
Interest
4,041,059
3,395,773
Interest/NOPBT
2.03%
1.02%